Study of Efficacy and Safety of LEE011 in Premenopausal Women With Advanced Breast Cancer : A Phase III randomized, double-blind, placebo-controlled study of LEE011 or placebo in combination with tamoxifen and goserelin or a non-steroidal aromatase inhibitor (NSAI) and goserelin for the treatment of premenopausal women with hormone receptor positive, HER2-negative, advanced breast cancer - Monaleesa-7

Medienart:

Klinische Studie

Erscheinungsjahr:

2022

Erschienen:

2022

Enthalten in:

WHO International Clinical Trials Registry Platform - (2022) vom: 08. Aug. Zur Gesamtaufnahme - year:2022

Sprache:

Englisch

Links:

Volltext [kostenfrei]

Themen:

610
Medical Condition: premenopausal women with hormone receptor positive, HER2-negative, advanced breast cancer MedDRA version: 21.1Level: LLTClassification code 10072737Term: Advanced breast cancerSystem Organ Class: 100000004864;Therapeutic area: Diseases [C] - Cancer [C04]
Phase: Phase 3
Recruitment Status: Not yet recruiting
Study Type: Interventional

Anmerkungen:

WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 28-10-2014, Last updated: 2022-11-24

ICTRP ID:

EUCTR2014-001931-36-DE
CLEE011E2301
2014-001931-36-HU

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

WHO004387333